Virus-like particles (VLPs) have become key tools in biology, medicine and even
engineering. After their initial use to resolve viral structures at the atomic level, VLPs were …

Since the first use of Chinese hamster ovary (CHO) cells for recombinant protein expression,
production processes have steadily improved through numerous advances. In this review …

The manufacture of recombinant therapeutics is a fastest-developing section of therapeutic
pharmaceuticals and presently plays a significant role in disease management. Yeasts are …

Most of the hosts used to produce the 151 recombinant pharmaceuticals so far approved for
human use by the Food and Drug Administration (FDA) and/or by the European Medicines …

Viral infectious diseases threaten human health and global stability. Several vaccine
platforms, such as DNA, mRNA, recombinant viral vectors, and virus-like particle-based …

In presently licensed vaccines, killed or attenuated organisms act as a source of
immunogens except for peptide-based vaccines. These conventional vaccines required a …

Pichia pastoris is currently one of the most effective and versatile systems for the expression
of heterologous proteins. Its success is due to its powerful methanol-inducible alcohol …

Nowadays, viruses are not only seen as causative agents of viral infectious diseases but
also as valuable research materials for various biomedical purposes, including recombinant …

Background State-of-the-art strain engineering techniques for the host Pichia pastoris (syn.
Komagataella spp.) include overexpression of homologous and heterologous genes, and …

Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling
viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating …